Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accrued Expenses (Details)

v3.21.2
Schedule of Accrued Expenses (Details) - USD ($)
Sep. 30, 2021
Dec. 31, 2020
Payables and Accruals [Abstract]    
Payroll and incentives $ 944,000 $ 1,094,000
General and administrative expenses 217,000 280,000
Research and development expenses 501,000 778,000
Deferred revenue and other deferred liabilities * [1] 1,232,000 643,000
Total $ 2,893,903 $ 2,795,329
[1] At September 30, 2021, there was approximately $1,199 thousand deferred liability under the Cystic Fibrosis Foundation (“CFF”) agreement and approximately $33 thousand in deferred revenue related to the Genentech Agreement. The Company expects to recognize the deferred revenue and deferred liabilities within the next 12 months. At December 31, 2020, there was an approximately $577 thousand deferred liability under the CFF Agreement and approximately $67 thousand in deferred revenue related to the Genentech Agreement. (See Note 9 – Collaboration Agreements, Licenses and Other Research and Development Agreements).